News releases from Adaptimmune Therapeutics plc

< Previous 1 2 3 4 5 6 Next >

Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

January 13, 2020

Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma

December 03, 2019

Will enable expedited development and review of ADP-A2M4 with the goal of commercialization in 2022 for patients with few other treatment options

Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma

November 16, 2019

Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update

November 06, 2019

Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019

November 01, 2019

Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies

October 09, 2019

Key step toward commercial-readiness for ADP-A2M4 therapy with launch planned for 2022

Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer

October 01, 2019

Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO

September 30, 2019

- Clinical responses in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out 12 patients -

United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4

September 09, 2019

Orphan drug designation is another significant milestone in the ADP-A2M4 program

New Executive Team Announced at Adaptimmune

August 01, 2019

Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update

August 01, 2019

Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019

July 29, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second Quarter 2019 and provide a business update before the U.S. markets...

Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS

July 25, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has started its SPEARHEAD-1 trial with ADP-A2M4 SPEAR T‑cells for patients with synovial sarcoma or myxoid/round...

Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center

July 22, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated a radiation sub-study of its ADP‑A2M4 trial in collaboration with the University of Texas MD...

Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses

July 18, 2019

These next-generation SPEAR T-cells may improve long term T-cell functions

Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer

June 27, 2019

James Noble will transition to become a Non-Executive Director

Adaptimmune Reports First Quarter 2019 Financial Results

May 06, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2019. Adaptimmune shared a clinical update...

Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors

May 06, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced significant clinical progress with partial responses in 4 out of 5 synovial sarcoma patients...

Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting

May 02, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present new and compelling data during an oral presentation about its off-the-shelf SPEAR T-cell program at...

Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019

May 01, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and business update before the U.S. markets open on Monday May 6, 2019. Following the...

Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting

April 18, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces an oral presentation by Dr. Jo Brewer, VP of Platform Sciences, summarizing data from Adaptimmune’s...

Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting

April 02, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from...

Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting

April 01, 2019

- Preclinical data show that next generation SPEAR T-cells may improve long term T-cell functions as well as antitumor activity -

CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update

February 27, 2019

In a release issued under the same headline earlier today by Adaptimmune Therapeutics plc (Nasdaq:ADAP), please note that the third subheadline should read, "Treating patients in expansion phases of...

Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update

February 26, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2018 and provided a business...

Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019

February 07, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Fourth Quarter / Full Year 2018 and provide a general business update...

Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews

January 06, 2019

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP...

Adaptimmune Announces that Gwen Binder will leave in January 2019

December 12, 2018

Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder, PhD, Chief Technology Officer, will be leaving the company at the end of January 2019.

Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update

November 05, 2018

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the third quarter ended September 30, 2018, and provided a business update.

Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018

October 25, 2018

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S....

< Previous 1 2 3 4 5 6 Next >

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.